Back

Delays in diagnosis and treatment initiation of ATTR cardiac amyloidosis: a real-world data analysis

31 August 2024 (10:00 - 10:50)
Organised by: Logo
Congress Presentation Part of: Cardiac amyloidosis, sarcoidosis, and inflammation Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Julia Kirsten Vogel

University of Duisburg-Essen - West-German Heart and Vascular Centre, Essen (Germany)

8 More presentations in this session

Presentation thumbnail
Transthyretin stabiliser therapy in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis
Mr V. Ribeiro (Teresina, BR)
Abstract Slides Video
Presentation thumbnail
Prevalence of transthyretin amyloid cardiomyopathy in patients hospitalised for heart failure with preserved ejection fraction in an LATAM center.
Mr S. Decotto (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
Biomarkers for monitoring patients with cardiac amyloidosis during transthyretin-stabilizer therapy
Doctor J. Vogel (Essen, DE)
Abstract Slides
Presentation thumbnail
Relationship between changes in renal function after acute phase of tafamidis administration and left ventricular diastolic function at mid-term follow-up in transthyretin cardiac amyloidosis
Ms A. Senda (Kobe, JP)
Abstract Slides
Presentation thumbnail
Prevalence of amyloidosis among patients with mild to severe aortic stenosis. Validation of screening parameters.
Doctor F. Voss (Duesseldorf, DE)
Abstract Slides

Access the full session

Session thumbnail
Cardiac amyloidosis, sarcoidosis, and inflammation

The Event

Event poster

ESC Congress 2024

31 August 2024 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Time from first recorded clinical manifestation to diagnosis of transthyretin amyloid cardiomyopathy: a retrospective cohort study using US claims data
thumbnail
Congress Presentation
Diagnostic lag and time to transthyretin stabilizer therapy in wild-type transthyretin amyloid cardiomyopathy
thumbnail
Congress Presentation
Changes in the diagnostic landscape of transthyretin amyloid cardiomyopathy (ATTR-CM): a comparison of tests ordered and test Intervals in 2020 Q4 and 2023 Q4

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources